{"schema_version":"secwatch.filing_event.v1","accession":"0001808805-22-000003","form_type":"8-K","ticker":"NAUT","cik":"0001808805","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2022-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.336826+00:00","generated_at":"2026-06-27T04:59:39.831252+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nautilus Biotechnology reports FY2021 net loss of $50.3M; operating expenses up 221% to $50.5M","bullets":["FY2021 net loss $50.3M, compared to $15.6M in 2020; operating expenses $50.5M, up 221%.","Cash, equivalents, investments $362.1M as of Dec 31, 2021; raised ~$345.5M via SPAC merger in June 2021.","Research collaborations with Amgen and MD Anderson; strategic partnership with Abcam for reagents.","Platform commercialization targeted by end of 2023; published PrISM proteomics approach."],"urls":{"canonical":"https://secwatch.observer/filing/0001808805-22-000003","json":"https://secwatch.observer/filing/0001808805-22-000003.json","markdown":"https://secwatch.observer/filing/0001808805-22-000003.md","text":"https://secwatch.observer/filing/0001808805-22-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000003/0001808805-22-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808805/000180880522000003/naut-20220224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T04:59:39.831252+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}